Ascendis Pharma has been granted a patent for an IL-2 protein sequence for cancer treatment. The invention involves a specific sequence and conjugates for effective therapy. GlobalData’s report on Ascendis Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ascendis Pharma AS - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ascendis Pharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Ascendis Pharma's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11879001B2) discloses a series of claims related to conjugates or pharmaceutically acceptable salts thereof. These conjugates consist of an IL-2 moiety of SEQ ID NO:14 linked to a moiety Mmod of specific formulas. The claims detail variations in the values of parameters such as b2, b3, and p1, p2, p3, and p4, with specific ranges and relationships defined for each parameter. The patent covers different configurations of the conjugates, allowing for flexibility in the design and formulation of these pharmaceutical compositions.

Furthermore, the patent also includes claims related to mixtures comprising these conjugates or salts, providing a comprehensive framework for the combination and utilization of the disclosed compounds. The mixtures may contain multiple conjugates with varying properties, as specified in the claims. By defining parameters such as b2, b3, and p1, p2, p3, and p4 for the mixtures, the patent offers a structured approach to the development and application of these compositions. Overall, the patent aims to protect the intellectual property associated with these specific conjugates and their mixtures, offering potential benefits in the field of pharmaceutical research and development.

To know more about GlobalData’s detailed insights on Ascendis Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies